Early Thursday, Takeda revealed top-line data for two pivotal phase 3 trials of its next-gen, highly selective oral tyrosine ...
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development ...
Hosted on MSN
Summit Therapeutics outlines ivonescimab progress with key Phase III data expected mid-2025
Co-CEO Bob Duggan highlighted significant progress with ivonescimab, Summit Therapeutics' lead investigational asset, emphasizing its potential impact on unmet medical needs. Key milestones included ...
SSC Phase 13 Answer Key 2025 : SSC Selection Post Answer Key 2025 is likely to be released soon by the Staff Selection Commission. The SSC Selection Post Phase 13 Answer Key 2025 which is generally ...
Nektar Therapeutics has two Phase IIb studies underway for rezpeg in atopic dermatitis and severe alopecia areata, with read-outs expected in 1H'25. Success in either indication would significantly ...
GRI Bio, Inc. has announced expected interim and topline data readouts from its Phase 2a biomarker study for the lead program GRI-0621, aimed at treating idiopathic pulmonary fibrosis (IPF), in Q2 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback